Interim analysis of a single-arm, phase II study of bevacizumab (BV) with modified OPTIMOX1 as first-line treatment of patients with metastatic colorectal cancer (mCRC): TCOG-GI0802

被引：0
|
作者：
Asano, M. [1 ]
Tanaka, S. [1 ]
Sato, A. [1 ]
Nakayama, N. [1 ]
Shimada, K. [1 ]
Konishi, K. [1 ]
Hibi, K. [1 ]
Sasaki, E. [1 ]
Kurihara, M. [1 ]
机构：
[1] Tokyo Cooperat Oncol Grp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
578
引用
收藏
页数：1
相关论文
共 50 条
  • [41] MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer
    Alexios Matikas
    John Souglakos
    Panagiotis Katsaounis
    Athanasios Kotsakis
    Panagiotis Kouroupakis
    Nikolaos Pantazopoulos
    Nikolaos Kentepozidis
    Adamantia Nikolaidi
    Ippokratis Messaritakis
    Ioanna Tzovara
    Dora Hatzidaki
    Efthymis Prinarakis
    Vassilis Georgoulias
    Targeted Oncology, 2019, 14 : 285 - 293
  • [42] A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Hochster, Howard S.
    Hart, Lowell L.
    Firdaus, Irfan
    Mace, Joseph Ronald
    McFarlane, Joshua Jemison
    Kozloff, Mark
    Catenacci, Daniel Virgil Thomas
    Hsu, Jessie J.
    Hack, Stephen Paul
    Shames, David S.
    Phan, See-Chun
    Cohn, Allen Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [43] MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer
    Matikas, Alexios
    Souglakos, John
    Katsaounis, Panagiotis
    Kotsakis, Athanasios
    Kouroupakis, Panagiotis
    Pantazopoulos, Nikolaos
    Kentepozidis, Nikolaos
    Nikolaidi, Adamantia
    Messaritakis, Ippokratis
    Tzovara, Ioanna
    Hatzidaki, Dora
    Prinarakis, Efthymis
    Georgoulias, Vassilis
    TARGETED ONCOLOGY, 2019, 14 (03) : 285 - 293
  • [44] Capecitabine and oxaliplatin as first-line treatment in patients with metastatic colorectal cancer (MCRC): A pooled analysis of randomized phase II-III trials
    Porschen, R.
    Arkenau, H.
    Arnold, D.
    Cassidy, J.
    Diaz-Rubio, E.
    Douillard, J.
    Grothey, A.
    Hinke, A.
    Schmiegel, W.
    Schmoll, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies
    Yuki, Satoshi
    Fukushima, Hiraku
    Amano, Toraji
    Nakamura, Michio
    Kudo, Mineo
    Sonoda, Norikazu
    Tateyama, Miki
    Kawamoto, Yasuyuki
    Hatanaka, Kazuteru
    Sogabe, Susumu
    Miyagishima, Takuto
    Akakura, Nobuaki
    Kato, Takashi
    Takagi, Tomofumi
    Iwanaga, Ichiro
    Miyashita, Kencho
    Onodera, Manabu
    Saitoh, Soh
    Sakata, Yuh
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] First-Line Treatment of Locally Advanced or Metastatic Pulmonary Lymphoepitheliomalikecarcinoma: A Multicenter, Single-Arm, Phase II Trial
    Zhou, C.
    Lin, X.
    Li, S.
    Sun, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S96 - S97
  • [47] Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302)
    Lapeyre-Prost, Alexandra
    Pernot, Simon
    Sigrand, Julie
    Le Malicot, Karine
    Mary, Florence
    Aparicio, Thomas
    Dahan, Laetitia
    Caroli-Bosc, Francois-Xavier
    Lecomte, Thierry
    Doat, Solene
    Marthey, Lysianne
    Desrame, Jerome
    Lepage, Come
    Taieb, Julien
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 285 - 290
  • [48] Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer
    Yamada, Yasuhide
    Yamaguchi, Tatsuro
    Matsumoto, Hiroshi
    Ichikawa, Yasushi
    Goto, Ayumu
    Kato, Ken
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1690 - 1696
  • [49] Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer
    Yasuhide Yamada
    Tatsuro Yamaguchi
    Hiroshi Matsumoto
    Yasushi Ichikawa
    Ayumu Goto
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhiro Shimada
    Investigational New Drugs, 2012, 30 : 1690 - 1696
  • [50] Bevacizumab (BV) plus chemotherapy (CT) as first-line treatment of patients with metastatic colorectal cancer (mCRC): First results from a large community-based observational cohort study in Germany
    Arnold, D.
    Kindler, M.
    Petersen, V.
    Tummes, D.
    Moelle, M.
    Schoeberl, C.
    Srock, S.
    Kutscheidt, A.
    Grothe, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : CP19 - U123
12345